Paperonium

Arthritis drugs · JAMA Netw Open · 2024

The paper’s summary: JAK-blocker drugs clearly raise cancer risk. Its own numbers allow for no difference.

The paper’s summary:JAK blockersclearly higherIts own rangecould be no differenceAbatacept, for comparisonall above 1×: clearly higherRituximab, for comparisonall above 1×: clearly higher1.36×0.94 to 1.96×0.7×1×1.5×2×3×5×no difference from TNF blockerslower riskhigher risk
The paper’ssummary:JAK blockersclearly higherIts own rangecould be nodifferenceAbatacept, forcomparisonall above 1×:clearly higherRituximab, forcomparisonall above 1×:clearly higher1.36×0.94×1.960.5×1×2×5×no difference fromTNF blockerslower riskhigher risk

Cancer risk, as a multiple of the risk on TNF blockers

The paper says

The paper compares cancer risk in people with rheumatoid arthritis starting various immune-calming drugs against people starting one kind, TNF blockers. Its summary says JAK blockers, like two other drugs (rituximab and abatacept), had a “significantly” (clearly) higher risk: 1.36 times as likely, 36% more.

Its own data show

The 1.36 is reported correctly; “significantly” is not. The summary itself prints the range of values its data can’t rule out: 0.94 to 1.96 times, from 6% lower risk to 96% higher. That includes 1×, no difference. Its discussion and closing conclusions agree: only rituximab and abatacept were clearly higher.

Researchers call a risk “significantly” higher only when its whole range sits above 1×, ruling out “no difference”. This range covers both no difference and nearly double: not proof of harm, nor of safety. It matters because an earlier trial found more cancer on a JAK blocker than on TNF blockers; the summary presents this study as clear backing.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk · JAMA Netw Open (2024) · doi:10.1001/jamanetworkopen.2024.46336